Uncategorized

Schedule a 1:1 meeting with our experts to see how this treatment (and others) can impact you HERE The U.S. Food and Drug Administration (FDA) approved Duvyzat (givinostat) for the treatment of Duchenne Muscular Dystrophy (DMD) in patients six years of age and older. Duvyzat is the first nonsteroidal drug approved to treat individuals with…

Know More

Treatment with givinostat — an oral therapy currently up for approval in the U.S. and Europe — significantly slowed motor function loss among boys with Duchenne muscular dystrophy (DMD) in the Phase 3 clinical trial EPIDYS, according to the full study results. Those results were detailed in a paper titled “Safety and efficacy of givinostat…

Know More

The U.S. Food and Drug Administration (FDA) has approved Italfarmaco’s givinostat, which will now be marketed as Duvyzat, as an oral suspension to treat people with Duchenne muscular dystrophy (DMD) ages 6 and older. Duvyzat becomes the first nonsteroidal therapy approved in the U.S. for patients with all genetic variants of DMD — the most…

Know More

Following the FDA’s approval of DUVYZAT (givinostat) on March 21, 2024, ITF Therapeutics, LLC, the company responsible for producing and marketing DUVYZAT in the United States, today shared an update on the drug and related resources. ITF Therapeutics has launched the DUVYZAT website, which provides Indication and Important Safety Information, a comprehensive list of FAQs,…

Know More

Going to college can be a life changing experience – from meeting new friends to expanding your knowledge to learning more about yourself. It can also be especially challenging while living with a rare condition like Duchenne muscular dystrophy. That’s where these scholarships aimed at individuals with Duchenne and those with other disabilities can come…

Know More

Earlier this month, more than 120 PPMD advocates – people with Duchenne and Becker, parents, siblings, grandparents, and other family members and friends – from 26 different states gathered in Washington, D.C. to urge legislators in the U.S. Senate and House of Representatives to keep Duchenne and Becker at the forefront of their minds when…

Know More

Sarepta Therapeutics recently joined PPMD for a community webinar: Data Update From the MOMENTUM Study of SRP-5051. Sarepta Therapeutics was invited to share data from Part B of MOMENTUM, a Phase 2 Study of SRP-5051 in people living with Duchenne muscular dystrophy who are amenable to skipping exon 51. Sarepta shared efficacy findings, noting that…

Know More

PTC Therapeutics, Inc. has announced that based on recent feedback from the FDA, the company plans to re-submit a New Drug Application (NDA) for Translarna (ataluren), a dystrophin restoration therapy via stop-codon readthrough for the treatment of nonsense mutation Duchenne (nmDMD). PTC expects to make the NDA resubmission by mid-2024. PPMD previously held a webinar…

Know More

Agamree (vamorolone) is now available for Duchenne muscular dystrophy (DMD) patients, ages 2 and older, in the U.S., where it will be dispensed through a specialty pharmacy network. The U.S. Food and Drug Administration (FDA) approved the next-generation steroid, expected to be more tolerable than standard DMD corticosteroids, in October. It will be marketed by…

Know More

Italfarmaco S.p.A. has announced that the full results from the pivotal phase 3 EPIDYS clinical trial of givinostat in ambulant Duchenne patients six years of age and older have been published in The Lancet Neurology. Givinostat is Italfarmaco’s proprietary histone deacetylase (HDAC) inhibitor for the potential treatment of Duchenne. The EPIDYS clinical trial met its…

Know More